Search results for "T-cell lymphoma"

showing 10 items of 32 documents

Constitutive psgl-1 correlates with cd30 and tcr pathways and represents a potential target for immunotherapy in anaplastic large t-cell lymphoma

2021

Simple Summary P-selectin glycoprotein ligand-1 (PSGL-1), coded by the SELPLG gene, is the major ligand of selectins and plays a pivotal role in tethering, rolling and extravasation of immune cells. PSGL-1 involvement in core molecular programs, such as SYK, PLCγ2, PI3Kγ or MAPK pathways, suggests additional functions beyond the modulation of cell trafficking. Recently, several studies identified a novel mechanism responsible for PSGL-1-mediated immune suppression in the tumor microenvironment and proved a novel concept of PSGL-1 as a critical checkpoint molecule for tumor immunotherapy. The immunotherapeutic approach has gained an ever-growing interest in the treatment of several hematolog…

0301 basic medicineCancer ResearchPTCLCD30medicine.medical_treatmentSykLymphoproliferative disordersBiologyALCL; ALK; CD30; Immunotherapy; PSGL-1; PTCL; TCRArticle03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesmedicineT-cell lymphomaPSGL-1RC254-282integumentary systemT-cell receptorNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapymedicine.diseaseALCLLymphomaGene expression profiling030104 developmental biologyOncologyALK030220 oncology & carcinogenesisCD30Cancer researchImmunotherapyTCR
researchProduct

T-Cell Lymphoma Clonality by Copy Number Variation Analysis of T-Cell Receptor Genes

2021

Simple Summary T-cells defend the human body from pathogenic invasion via specific recognition by T-cell receptors (TCRs). The TCR genes undergo recombination (rearrangement) in a myriad of possible ways to generate different TCRs that can recognize a wide diversity of foreign antigens. However, in patients with T-cell lymphoma (TCL), a particular T-cell becomes malignant and proliferates, resulting in a population of genetically identical cells with same TCR rearrangement pattern. To help diagnose patients with TCL, a polymerase chain reaction (PCR)-based assay is currently used to determine if neoplastic cells in patient samples are of T-cell origin and bear identical (monoclonal) TCR rea…

0301 basic medicineclone (Java method)Cancer ResearchclonalityBiologylcsh:RC254-282Article03 medical and health sciences0302 clinical medicinemedicineT-cell lymphomaT-cell receptorCopy-number variationcopy number variation analysisGeneWhole genome sequencingwhole genome sequencingT-cell receptorlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMolecular biology030104 developmental biologyOncology030220 oncology & carcinogenesisT-Cell Receptor GeneMonoclonalT-cell lymphomaClonality Copy number variation analysis T-cell lymphoma T-cell receptor Whole genome sequencingCancers
researchProduct

Granulomatous slack skin: report of a case associated with Hodgkin's disease and a review of the literature.

1994

We report a case of granulomatous slack skin (GSS) associated with Hodgkin's disease, and review the literature on this entity. GSS, a variant of cutaneous T-cell lymphoma, clinically presents with erythematous patches in the flexures, which gradually transform into bulky, pendulous areas of skin. Histology shows an elastolytic granulomatous infiltrate, with atypical lymphoid cells, and occasional epidermotropism. As far as we are aware, 10 cases of GSS, including our patient, have been reported in detail. The male:female ratio of these cases is 9:1, and the age range 15-51 years. Five cases were associated with Hodgkin's disease, one with small lymphocytic lymphoma, and one developed cutan…

AdultMalePathologymedicine.medical_specialtyAdolescentmedicine.medical_treatmentDermatologychemistry.chemical_compoundMaintenance therapyhemic and lymphatic diseasesmedicineHumansSkinChemotherapyChlorambucilbusiness.industryGranulomatous slack skinMiddle Agedmedicine.diseaseHodgkin DiseaseNitrogen mustardPeripheral T-cell lymphomaLymphomaLymphoma T-Cell CutaneousRadiation therapychemistrybusinessmedicine.drugThe British journal of dermatology
researchProduct

Low incidence but poor prognosis of complicated coeliac disease: A retrospective multicentre study.

2013

Abstract Background Coeliac disease is a chronic enteropathy characterized by an increased mortality caused by its complications, mainly refractory coeliac disease, small bowel carcinoma and abdominal lymphoma. Aim of the study was to study the epidemiology of complications in patients with coeliac disease. Methods Retrospective multicenter case–control study based on collection of clinical and laboratory data. The incidence of complicated coeliac disease was studied among coeliac patients directly diagnosed in four Italian centres. Patients referred to these centres after a diagnosis of coeliac disease and/or complicated coeliac disease in other hospitals were therefore excluded. Results B…

AdultMalePediatricsmedicine.medical_specialtyPoor prognosisLymphoma B-CellSettore MED/09 - Medicina InternaComplicationsCELIAC DISEASEcomplicated coeliac diseaseKaplan-Meier EstimateGastroenterologyCoeliac diseaseNOCohort StudiesEnteropathy-Associated T-Cell LymphomaRefractoryCELIAC DISEASE; ComplicationsInternal medicineEpidemiologyIntestinal NeoplasmsIntestine SmallmedicinePrevalenceHumansAgedRetrospective StudiesHepatologybusiness.industryIncidence (epidemiology)IncidenceCarcinomaGastroenterologyCurve analysisnutritional and metabolic diseasesMiddle Agedmedicine.diseasePrognosisdigestive system diseasesLymphomaItalyAbdominal NeoplasmsCase-Control StudiesCohortFemalebusiness
researchProduct

Risk of Non-Hodgkin Lymphoma in Celiac Disease

2002

CONTEXT: Celiac disease is one of the most common lifelong disorders. Non-Hodgkin lymphoma is a possible complication of celiac disease and may lead to a large portion of lymphoma cases. OBJECTIVE: To quantify the risk for developing non-Hodgkin lymphoma of any primary site associated with celiac disease. DESIGN AND SETTING: Multicenter, case-control study conducted between January 1996 and December 1999 throughout Italy. PATIENTS: Cases were older than 20 years (median, 57; range, 20-92 years) with non-Hodgkin lymphoma of any primary site and histological type and were recruited at the time of the diagnosis. Controls were healthy adults (2739 men and 2981 women) from the general population…

AdultMalemedicine.medical_specialtyPathologyLymphoma B-CellSettore MED/09 - Medicina InternaPopulationLymphoma T-CellNon-Hodgkin lymphoma; celiac diseaseGastroenterologyCoeliac diseaseRisk Factorsimmune system diseaseshemic and lymphatic diseasesInternal medicineImmunopathologymedicineHumansT-cell lymphomaNon-hodgkin diseaseeducationMass screeningAgedNon-Hodgkin lymphomaAged 80 and overeducation.field_of_studybusiness.industryLymphoma Non-HodgkinCase-control studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLymphomaCase-Control StudiesFemalebusinessceliac diseaseJAMA
researchProduct

Photochemotherapy Alone or Combined with Interferon Alpha-2a in the Treatment of Cutaneous T-Cell Lymphoma

1990

Eighty-two patients with either mycosis fungoides (MF) or parapsoriasis en plaques were treated with psoralens ultraviolet A light (PUVA). Clinical and histologic parameters were followed for a period from 6 months to 10 years. Complete clinical clearing of lesions was observed in 51 patients (62%) and most of them were in limited-plaque MF group or parapsoriasis en plaque. The mean total dose of PUVA for complete clearing was less for early MF. Thirty-one patients (38%) relapsed and responded to additional PUVA. Patients in early stages of the disease remained clear for up to 68 months after the first course of PUVA. Post-treatment skin biopsies with early MF showed histologic clearing. A …

AdultMalemedicine.medical_specialtySkin NeoplasmsCombination therapyConstitutional symptomsDermatologyInterferon alpha-2BiochemistryMycosis FungoidesInterferonmedicineHumansSezary SyndromePUVA TherapyMolecular BiologyDepression (differential diagnoses)AgedNeoplasm StagingMycosis fungoidesParapsoriasisbusiness.industryCutaneous T-cell lymphomaInterferon-alphaCell BiologyMiddle Agedmedicine.diseaseCombined Modality TherapyDermatologyRecombinant ProteinsLymphoma T-Cell CutaneousDrug EvaluationFemalebusinessProgressive diseasemedicine.drugJournal of Investigative Dermatology
researchProduct

Mast Cells and Th17 Cells Contribute to the Lymphoma-Associated Pro-Inflammatory Microenvironment of Angioimmunoblastic T-Cell Lymphoma

2010

Reports focusing on the immunological microenvironment of peripheral T-cell lymphomas (PTCL) are rare. Here we studied the reciprocal contribution of regulatory (Treg) and interleukin-17-producing (Th17) T-cells to the composition of the lymphoma-associated microenvironment of angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified on tissue microarrays from 30 PTCLs not otherwise specified and 37 AITLs. We found that Th17 but not Treg cells were differently represented in the two lymphomas and correlated with the amount of mast cells (MCs) and granulocytes, which preferentially occurred in the cellular milieu of AITL cases. We observed that MCs directly synthesized inter…

Angioimmunoblastic T-cell lymphomaLymphomaInflammationBiologymedicine.disease_causeCXCR3Lymphoma T-CellCXCR5Pathology and Forensic MedicineAutoimmunityAnimals Chemokine CXCL13; immunology Cytokines; genetics/immu/nology Forkhead Transcription Factors; immunology Gene Expression Profiling Humans Immunoblastic Lymphadenopathy; immunology/pathology Inflammation; immunology Interleukin-17; immunology Interleukin-6; immunology Lymphoma; T-Cell; immunology/pathology Mast Cells; immunology Microarray Analysis Th17 Cells; immunology Tumor MicroenvironmentimmunologymedicineTumor MicroenvironmentAnimalsHumansMast CellsInflammationTumor microenvironmentInterleukin-6Gene Expression ProfilingInterleukin-17Forkhead Transcription FactorsMast cellmedicine.diseaseT-CellMicroarray AnalysisChemokine CXCL13humanitiesgenetics/immu/nologyLymphomamedicine.anatomical_structureImmunoblastic LymphadenopathyImmunologyCytokinesimmunology/pathologyTh17 CellsMast Cell microenvironment angioimmunoblasticmedicine.symptomRegular Articles
researchProduct

Angioimmunoblastic T-cell lymphoma

2008

Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive neoplasm clinically characterized by sudden onset of constitutional symptoms, lymphadenopathy, hepatosplenomegaly, frequent autoimmune phenomena, particularly hemolytic anemia and thrombocytopenia, and polyclonal hypergammaglobulinemia. The lymph node histological picture is also distinctive, constituted by a polymorphic infiltrate, a marked proliferation of high endothelial venules, and a dense meshwork of dentritic cells. The neoplastic CD4+ T-cells represent a minority of the lymph node cell population; its detection is facilitated by the aberrant expression of CD10. Almost all cases arbor an EBV infected B-cell populatio…

CD4-Positive T-LymphocytesMaleEpstein-Barr Virus InfectionsPathologyAutologous transplantHerpesvirus 4 HumanHepatosplenomegalyImmunosuppressive AgentEpstein-Barr Virus InfectionHypergammaglobulinemiaLymph nodeNon-Hodgkin lymphomaAngioimmunoblastic lymphomaB-Lymphocyteseducation.field_of_studyB-LymphocyteLymph NodeHematologyThalidomideSurvival RateTransplantation Autologoumedicine.anatomical_structureOncologyCD4-Positive T-LymphocyteFemaleNeprilysinmedicine.symptomImmunosuppressive AgentsHumanmedicine.medical_specialtyAngioimmunoblastic T-cell lymphomaPopulationHigh endothelial venulesDendritic CellLymphoma T-CellTransplantation AutologousmedicineHumanseducationCell Proliferationbusiness.industryPeripheral T-cell lymphomaDendritic Cellsmedicine.diseasePeripheral T-cell lymphomaLymphomaTransplantationImmunologyLymph NodesGeriatrics and GerontologybusinessStem Cell Transplantation
researchProduct

Transmission of angioimmunoblastic T-cell lymphoma by bone marrow transplant

2014

Accidental transmission of lymphoma by bone marrow transplant is a rarely reported event [1–5], since candidates are only accepted for hematopoietic stem cell donation after a work-up that routinel...

Cancer ResearchAngioimmunoblastic T-cell lymphomaBone marrow transplantPathologymedicine.medical_specialtybusiness.industryTransmission (medicine)Hematopoietic stem cellHematologymedicine.diseaseLymphomamedicine.anatomical_structureOncologymedicinebusinessLeukemia & Lymphoma
researchProduct

From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas an…

2017

Background Notable progress has been made in chemo- and immunotherapy of B-cell lymphomas, but less in the treatment of T-cell lymphomas. Objective Histone deacetylases inhibitors are a potentially useful therapeutic mean, as an epigenetic dysregulation is present in lymphomas, and especially in T-cell types. We aimed to study the progress made in this area. Method A mini-review was achieved using the articles published in PubMed in the last two years and the new patents made in this field. Results Histone deacetylases inhibitors are involved in the derepression of tumor suppressor genes through a histone deacetylase-mediated transcriptional process. Their inhibition is followed by cell cyc…

Cancer ResearchDrug exportmedicine.medical_treatmentCellular differentiationAntineoplastic Agents010402 general chemistryLymphoma T-Cell01 natural sciencesHistone DeacetylasesRomidepsinPatents as TopicDrug DiscoveryPlasma Cell MyelomamedicineAnimalsHumansPharmacology (medical)Epigeneticsbiology010405 organic chemistrybusiness.industryDrug SynergismGeneral MedicineImmunotherapymedicine.diseasePeripheral T-cell lymphoma0104 chemical sciencesHistone Deacetylase InhibitorsHistoneOncologyDrug DesignImmunologyCancer researchbiology.proteinbusinessMultiple Myelomamedicine.drugRecent patents on anti-cancer drug discovery
researchProduct